Cervera Ricard
Department of Autoimmune Diseases, Institut Clínic of Medicine and Dermatology, Hospital Clínic, Barcelona, Catalonia, Spain.
Autoimmun Rev. 2008 Jan;7(3):174-8. doi: 10.1016/j.autrev.2007.11.011. Epub 2007 Dec 3.
The "Euro-Phospholipid" project started in 1999 with a multicentre, consecutive and prospective design. A total cohort of 1000 patients with antiphospholipid syndrome (APS), derived from 13 countries (Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Israel, Italy, the Netherlands, Portugal, Spain and United Kingdom), has been followed since then by a European consortium that was created as part of the network promoted by the "European Forum on Antiphospholipid Antibodies", a study group devoted to the development of multicentre projects with large populations of APS patients. This project allowed the identification of the prevalence and characteristics of the main clinical and immunological manifestations at the onset and during the evolution of APS and demonstrated that it is possible to recognize more homogeneous subsets of clinical significance.
“欧洲磷脂”项目始于1999年，采用多中心、连续和前瞻性设计。自那时起，一个由来自13个国家（比利时、保加利亚、丹麦、法国、德国、希腊、匈牙利、以色列、意大利、荷兰、葡萄牙、西班牙和英国）的1000名抗磷脂综合征（APS）患者组成的总队列，一直由一个欧洲联盟进行跟踪研究。该联盟是作为“欧洲抗磷脂抗体论坛”推动的网络的一部分而创建的，该论坛是一个致力于开展针对大量APS患者的多中心项目的研究小组。该项目有助于确定APS发病时及病程中主要临床和免疫表现的患病率及特征，并表明有可能识别出具有临床意义的更同质的亚组。
